Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
US Stem Cell's average Accounts Receivable for the
three
months ended in Dec. 2022 was $0.00 Mil. US Stem Cell's Revenue for the
three
months ended in Dec. 2022 was $0.02 Mil.
Hence, US Stem Cell's Days Sales Outstanding for the
three
months ended in Dec. 2022 was 15.97.
The historical rank and industry rank for US Stem Cell's Days Sales Outstanding or its related term are showing as below:
USRM's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 68.94 * Ranked among companies with meaningful Days Sales Outstanding only.
US Stem Cell's Days Sales Outstanding
declined
from Dec. 2021 (68.44) to Dec. 2022 (15.97).
US Stem Cell (OTCPK:USRM) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
US Stem Cell Days Sales Outstanding Related Terms
US Stem Cell Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for US Stem Cell's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
USRM vs NOVNQ, RGRX, NMTRQ: Days Sales Outstanding Comparison
For the Biotechnology subindustry, US Stem Cell's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
US Stem Cell Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, US Stem Cell's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where US Stem Cell's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
US Stem Cell (USRM) has a Days Sales Outstanding of 15.97 as of Dec. 2022. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on US Stem Cell and its competitors.
Is US Stem Cell's Days Sales Outstanding too high?
US Stem Cell's current Days Sales Outstanding is 15.97. The Biotechnology industry median Days Sales Outstanding is 68.94. US Stem Cell's value of 15.97 is 76.8% below this industry median. Overall, US Stem Cell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does US Stem Cell's Days Sales Outstanding compare to NOVNQ and RGRX?
US Stem Cell's Days Sales Outstanding of 15.97 can be compared against companies in the Biotechnology industry. The industry median Days Sales Outstanding is 68.94. US Stem Cell's value of 15.97 is 76.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. US Stem Cell's current Days Sales Outstanding of 15.97 is 76.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on US Stem Cell and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. US Stem Cell's current Days Sales Outstanding is 15.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is US Stem Cell stock overvalued right now?
US Stem Cell (USRM) has a current Days Sales Outstanding of 15.97. The current Days Sales Outstanding is 15.97 and 76.8% below the Biotechnology industry median of 68.94. US Stem Cell's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For US Stem Cell (USRM), the current Days Sales Outstanding is 15.97 as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
12GF Score
Get the complete analysis for USRM
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
USRM has been successfully added to your 
